✦ LIBER ✦

O-087 Many patients 80 years and older with advanced NSCLC toleratechemotherapy

✍ Scribed by Altundag, O.; Fossella, F.; Ayers, G.; Zinner, R.

Book ID: 118572635
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 131 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(05)80221-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of sorafenib in very

Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma

✍ Jo, Masayasu; Yasui, Kohichiroh; Kirishima, Toshihiko; Shima, Toshihide; Niimi, 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 512 KB

Phase 2 trial of docetaxel and gefitinib

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

✍ George R. Simon; Martine Extermann; Alberto Chiappori; Charles C. Williams; Mube 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

## Abstract ## BACKGROUND This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progress

9147 POSTER Treatment and Clinical Outco

9147 POSTER Treatment and Clinical Outcomes of Young Patients (^40 Years) With Advanced Non-small Cell Lung (NSCLC) – Data From a Retrospective Multicentric Database

✍ Caffo, O.; Ceribelli, A.; De Marinis, F.; Bulotta, A.; Novello, S.; Bearz, A.; D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB